SomaLogic, Inc.
SLGCW
NASDAQ Global Market0.09
USD
-0.03
- -
CIK
0001837412
ISIN
US83444K1135
CUSIP
83444K113
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-91.13
76.60
5Y
-96.16
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Stephen A. Williams BS, MB,
- Full Time Employees
- 451
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 2945 Wilderness Place Boulder CO United States of America 80301
- IPO Date
- Sep 2, 2021
- CIK
- 0001837412
- Website
- somalogic.com
- Similar Companies
- Business
- SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company focused on proteomics technology. The company develops slow off-rate modified aptamers, or SOMAmers, which are modified nucleic acid-based protein binding reagents specific to target proteins; offers proprietary SomaScan services, a high-plex proteomics platform that enables multiplex detection and quantification of up to 11,000 proteins in complex biological samples such as plasma, serum, CSF, and urine; and provides SomaSignal laboratory-developed tests for clinical insights across areas including cardiovascular risk, metabolic diseases, liver function, nonalcoholic steatohepatitis, and wellness. SomaScan panels are available in custom and disease-specific configurations for biomarker discovery, drug development, and diagnostic applications, serving pharmaceutical and biotechnology companies, academic institutions, and government research entities primarily in the United States with global collaborations. Founded in 2000 and headquartered in Boulder, Colorado, SomaLogic functions as a subsidiary of Standard BioTools Inc. following its acquisition in January 2024; in June 2025, Standard BioTools agreed to sell SomaLogic and related assets to Illumina Inc. for $350 million in cash plus up to $75 million in milestones and royalties, building on a multi-year co-development partnership with Illumina for NGS-based proteomic kits to advance multiomics and biomarker profiling.